The European Commission has granted approval for linzagolix (Yselty) for the treatment of endometriosis, marking a significant step forward for women's health. Developed by Kissei Pharmaceutical Co., Ltd., linzagolix, a GnRH antagonist, is already available in five European countries for the treatment of uterine fibroids. This additional indication promises to provide a new therapeutic option for women suffering from endometriosis, a condition often associated with severe pain and infertility.
Mechanism of Action
Linzagolix functions by antagonizing GnRH at the GnRH receptor in the pituitary gland. This action suppresses the secretion of gonadotropin, a gonadotrophic hormone, which in turn reduces estrogen production in the ovaries. By lowering estrogen levels, linzagolix helps to alleviate the symptoms of endometriosis, a condition characterized by the growth of endometrial-like tissue outside the uterus.
Global Development
Beyond Europe, linzagolix is under development by Kissei for both uterine fibroids and endometriosis in Japan. Theramex, a global specialty pharmaceutical company focused on women's health, holds the rights to linzagolix outside of Asia and has already launched the drug in Germany, Spain, Poland, Italy, and the United Kingdom. An approval application has also been submitted in Australia. In Asia, Synmosa BioPharma in Taiwan has filed for approval, while JW Pharma in South Korea is preparing to initiate development.
Endometriosis: A Significant Health Challenge
Endometriosis affects women primarily in their 20s and 30s and is a significant cause of abdominal pain and infertility. The condition involves the growth of endometrial tissue outside the uterus, leading to inflammation, scarring, and pain. The approval of linzagolix offers a new approach to managing this condition by targeting the hormonal pathways that drive its progression.
Kissei's Perspective
Kissei anticipates that the approval of linzagolix for endometriosis will not significantly impact its consolidated business forecasts for the fiscal year ending in March 2025. The company remains committed to developing and providing treatments that improve the quality of life for patients worldwide.
